Ekso BionicsEKSO
EKSO
About: Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The regions company operates in are the Americas, EMEA, and APAC.
Employees: 72
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
198% more capital invested
Capital invested by funds: $2.08M [Q2] → $6.2M (+$4.12M) [Q3]
13.91% more ownership
Funds ownership: 10.91% [Q2] → 24.82% (+13.91%) [Q3]
0% more funds holding
Funds holding: 28 [Q2] → 28 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2
222%
upside
Avg. target
$5.50
786%
upside
High target
$9
1,349%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Ben Haynor 14% 1-year accuracy 1 / 7 met price target | 222%upside $2 | Buy Maintained | 29 Oct 2024 |
HC Wainwright & Co. Swayampakula Ramakanth 29% 1-year accuracy 51 / 173 met price target | 1,349%upside $9 | Buy Maintained | 29 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Ekso Bionics to Showcase Its Device Technology in ‘AI for Good' Webinar on Tuesday, November 19
SAN RAFAEL, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Katherine Strausser, Principal Controls Engineer at Ekso Bionics, will be participating in an ‘AI for Good' webinar.
Neutral
GlobeNewsWire
1 month ago
Ekso Bionics to Participate at the 15th Annual Craig-Hallum Alpha Select Conference
SAN RAFAEL, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, Chief Executive Officer, and Jerome Wong, Chief Financial Officer, will be participating at the 15th Annual Craig-Hallum Alpha Select Conference taking place in New York on Tuesday, November 19, 2024.
Negative
Zacks Investment Research
1 month ago
Ekso Bionics (EKSO) Reports Q3 Loss, Misses Revenue Estimates
Ekso Bionics (EKSO) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.24 per share a year ago.
Neutral
Seeking Alpha
1 month ago
Ekso Bionics Holdings, Inc. (EKSO) Q3 2024 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Conference Call Participants Ben Haynor - Lake Street Capital Markets Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics Quarter Three 2024 Financial Results Call.
Neutral
GlobeNewsWire
1 month ago
Ekso Bionics Announces Third Quarter 2024 Financial Results
SAN RAFAEL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2024.
Neutral
GlobeNewsWire
2 months ago
Ekso Bionics to Report Third Quarter 2024 Financial Results on October 28, 2024
SAN RAFAEL, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2024 after the close of trading on Monday, October 28, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.
Neutral
GlobeNewsWire
3 months ago
Ekso Bionics Announces Pricing of $6.0 Million Underwritten Public Offering
SAN RAFAEL, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced the pricing of an underwritten public offering of 6,000,000 total units and pre-funded units for gross proceeds of approximately $6.0 million prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of 3,100,000 units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock, one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the fifth anniversary of the date of issuance (a “Series A Warrant”) and one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the first anniversary of the date of issuance (a “Series B Warrant”) and (ii) 2,900,000 pre-funded units, priced at a public offering price of $0.999 per unit, with each unit consisting of one pre-funded warrant to purchase one share of common stock at an exercise price of $0.001 per share, one Series A Warrant and one Series B Warrant. The securities comprising the units and pre-funded units are immediately separable and will be issued separately.
Positive
Zacks Investment Research
4 months ago
Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update
Ekso Bionics EKSO has reached a significant milestone in terms of transforming mobility solutions, particularly for individuals with spinal cord injuries (SCI). The company recently secured initial reimbursement from the Centers for Medicare & Medicaid Services (CMS) for its Ekso Indego Personal exoskeleton.
Negative
InvestorPlace
4 months ago
Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
Ekso Bionics (NASDAQ: EKSO ) stock is taking a beating on Tuesday following the release of the exoskeleton company's Q2 earnings report. The bad news for Ekso Bionics starts with its diluted earnings per share of -13 cents.
Neutral
Seeking Alpha
4 months ago
Ekso Bionics Holdings, Inc. (EKSO) Q2 2024 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Conference Call Participants Ben Haynor - Lake Street Capital Markets Li Chen - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics' Q2 2024 Financial Results Call.
Charts implemented using Lightweight Charts™